Market Closed -
Xetra
11:35:31 2024-06-07 am EDT
|
5-day change
|
1st Jan Change
|
148.2
EUR
|
0.00%
|
|
+3.42%
|
+21.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
132,331
|
131,461
|
181,878
|
210,243
|
209,128
|
247,656
|
-
|
-
|
Enterprise Value (EV)
1 |
144,340
|
143,328
|
206,261
|
233,166
|
231,638
|
268,078
|
261,373
|
254,871
|
P/E ratio
|
97.9
x
|
41
x
|
1,468
x
|
64.3
x
|
35.4
x
|
28.2
x
|
24
x
|
21.7
x
|
Yield
|
2.78%
|
2.8%
|
2.44%
|
2.14%
|
2.15%
|
1.93%
|
2.03%
|
2.11%
|
Capitalization / Revenue
|
5.43
x
|
4.94
x
|
4.86
x
|
4.74
x
|
4.57
x
|
4.8
x
|
4.46
x
|
4.22
x
|
EV / Revenue
|
5.92
x
|
5.38
x
|
5.51
x
|
5.26
x
|
5.06
x
|
5.19
x
|
4.71
x
|
4.34
x
|
EV / EBITDA
|
21.6
x
|
17.2
x
|
27.2
x
|
25.2
x
|
17.1
x
|
15
x
|
13
x
|
11.6
x
|
EV / FCF
|
72.5
x
|
37.3
x
|
42.3
x
|
26.7
x
|
25.8
x
|
30.9
x
|
22.3
x
|
18.7
x
|
FCF Yield
|
1.38%
|
2.68%
|
2.36%
|
3.74%
|
3.88%
|
3.24%
|
4.49%
|
5.35%
|
Price to Book
|
10
x
|
8.41
x
|
4.24
x
|
5.67
x
|
5.38
x
|
5.99
x
|
5.37
x
|
4.74
x
|
Nbr of stocks (in thousands)
|
1,311,913
|
1,312,660
|
1,549,159
|
1,549,528
|
1,549,926
|
1,550,256
|
-
|
-
|
Reference price
2 |
100.9
|
100.1
|
117.4
|
135.7
|
134.9
|
159.8
|
159.8
|
159.8
|
Announcement Date
|
2/14/20
|
2/11/21
|
2/10/22
|
2/9/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
24,384
|
26,617
|
37,417
|
44,351
|
45,811
|
51,620
|
55,503
|
58,721
|
EBITDA
1 |
6,686
|
8,311
|
7,586
|
9,237
|
13,580
|
17,920
|
20,101
|
21,883
|
EBIT
1 |
6,436
|
7,340
|
9,928
|
13,350
|
14,534
|
16,821
|
18,978
|
20,632
|
Operating Margin
|
26.39%
|
27.58%
|
26.53%
|
30.1%
|
31.73%
|
32.59%
|
34.19%
|
35.14%
|
Earnings before Tax (EBT)
1 |
1,548
|
3,916
|
-265
|
2,501
|
6,899
|
11,091
|
13,093
|
14,584
|
Net income
1 |
1,335
|
3,196
|
112
|
3,288
|
5,961
|
8,844
|
10,380
|
11,620
|
Net margin
|
5.47%
|
12.01%
|
0.3%
|
7.41%
|
13.01%
|
17.13%
|
18.7%
|
19.79%
|
EPS
2 |
1.030
|
2.440
|
0.0800
|
2.110
|
3.810
|
5.667
|
6.659
|
7.374
|
Free Cash Flow
1 |
1,990
|
3,838
|
4,872
|
8,717
|
8,984
|
8,684
|
11,745
|
13,640
|
FCF margin
|
8.16%
|
14.42%
|
13.02%
|
19.65%
|
19.61%
|
16.82%
|
21.16%
|
23.23%
|
FCF Conversion (EBITDA)
|
29.76%
|
46.18%
|
64.22%
|
94.37%
|
66.16%
|
48.46%
|
58.43%
|
62.33%
|
FCF Conversion (Net income)
|
149.06%
|
120.09%
|
4,350%
|
265.12%
|
150.71%
|
98.2%
|
113.15%
|
117.38%
|
Dividend per Share
2 |
2.800
|
2.800
|
2.870
|
2.900
|
2.900
|
3.078
|
3.244
|
3.373
|
Announcement Date
|
2/14/20
|
2/11/21
|
2/10/22
|
2/9/23
|
2/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
12,011
|
-
|
11,390
|
10,771
|
-
|
10,982
|
11,207
|
-
|
10,879
|
11,416
|
11,492
|
12,024
|
12,679
|
12,574
|
12,972
|
13,475
|
13,410
|
13,730
|
EBITDA
1 |
-
|
-
|
-
|
1,900
|
-
|
2,187
|
1,896
|
-
|
2,579
|
2,574
|
-
|
-
|
3,732
|
-
|
-
|
-
|
4,396
|
4,404
|
5,260
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
3,318
|
-
|
3,961
|
3,365
|
-
|
3,413
|
2,610
|
-
|
3,946
|
4,291
|
3,545
|
2,752
|
4,310
|
4,027
|
4,356
|
3,974
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
27.62%
|
-
|
34.78%
|
31.24%
|
-
|
31.08%
|
23.29%
|
-
|
36.27%
|
37.59%
|
30.85%
|
22.89%
|
33.99%
|
32.02%
|
33.58%
|
29.49%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-636
|
-
|
553
|
247
|
-
|
922
|
778
|
-
|
2,262
|
2,088
|
1,652
|
897
|
2,800
|
2,361
|
2,740
|
3,099
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-347
|
-
|
386
|
360
|
-
|
1,640
|
901
|
-
|
1,803
|
1,818
|
1,378
|
959
|
2,179
|
2,092
|
2,450
|
2,493
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-2.89%
|
-
|
3.39%
|
3.34%
|
-
|
14.93%
|
8.04%
|
-
|
16.57%
|
15.93%
|
11.99%
|
7.98%
|
17.19%
|
16.64%
|
18.89%
|
18.5%
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.2200
|
-
|
0.2500
|
0.2300
|
-
|
1.050
|
0.5800
|
-
|
1.160
|
1.170
|
0.8900
|
0.6200
|
1.410
|
1.341
|
1.569
|
1.600
|
-
|
-
|
Dividend per Share
2 |
0.9000
|
1.900
|
0.9000
|
1.970
|
1.970
|
-
|
0.9300
|
0.9300
|
-
|
1.970
|
1.970
|
-
|
0.9300
|
-
|
1.970
|
-
|
0.8875
|
0.7750
|
1.438
|
0.8750
|
0.8750
|
Announcement Date
|
7/30/20
|
2/11/21
|
7/29/21
|
2/10/22
|
2/10/22
|
4/29/22
|
7/29/22
|
7/29/22
|
11/10/22
|
2/9/23
|
2/9/23
|
4/27/23
|
7/28/23
|
11/9/23
|
2/8/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
12,009
|
11,867
|
24,383
|
22,923
|
22,510
|
20,422
|
13,718
|
7,215
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.796
x
|
1.428
x
|
3.214
x
|
2.482
x
|
1.658
x
|
1.14
x
|
0.6824
x
|
0.3297
x
|
Free Cash Flow
1 |
1,990
|
3,838
|
4,872
|
8,717
|
8,984
|
8,684
|
11,745
|
13,640
|
ROE (net income / shareholders' equity)
|
35.6%
|
36.7%
|
27.5%
|
27.2%
|
29.8%
|
30%
|
31.5%
|
30.6%
|
ROA (Net income/ Total Assets)
|
2.19%
|
4.99%
|
8.77%
|
3.26%
|
11.5%
|
9.36%
|
10.6%
|
11.4%
|
Assets
1 |
61,015
|
64,053
|
1,277
|
100,924
|
51,935
|
94,518
|
98,020
|
101,725
|
Book Value Per Share
2 |
10.10
|
11.90
|
27.70
|
23.90
|
25.10
|
26.70
|
29.70
|
33.70
|
Cash Flow per Share
2 |
2.280
|
3.660
|
4.180
|
6.290
|
6.620
|
8.540
|
10.40
|
11.50
|
Capex
1 |
979
|
961
|
1,091
|
1,091
|
1,361
|
1,991
|
1,958
|
1,938
|
Capex / Sales
|
4.01%
|
3.61%
|
2.92%
|
2.46%
|
2.97%
|
3.86%
|
3.53%
|
3.3%
|
Announcement Date
|
2/14/20
|
2/11/21
|
2/10/22
|
2/9/23
|
2/8/24
|
-
|
-
|
-
|
Last Close Price
159.8
USD Average target price
173.2
USD Spread / Average Target +8.39% Consensus |
1st Jan change
|
Capi.
|
---|
| +45.82% | 765B | | +40.95% | 632B | | -6.16% | 354B | | +19.86% | 331B | | +9.32% | 299B | | +11.88% | 216B | | -0.78% | 219B | | +5.90% | 164B | | -0.73% | 162B |
Other Pharmaceuticals
|